part 2: clinical utility of angiogenesis inhibitors in metastatic colorectal cancer
Published 11 years ago • 392 plays • Length 32:17Download video MP4
Download video MP3
Similar videos
-
10:49
part 3: clinical utility of angiogenesis inhibitors in metastatic colorectal cancer
-
41:03
part 1: clinical utility of angiogenesis inhibitors in metastatic colorectal cancer
-
18:58
mechanisms of angiogenesis inhibitors in metastatic colorectal cancer
-
15:55
enhancing outcomes in metastatic colorectal cancer with angiogenesis inhibitors
-
22:30
new directions in targeting angiogenesis for metastatic colorectal cancer
-
23:57
a comparison of angiogenesis inhibitor trial designs and outcomes in mcrc
-
10:54
metastatic gastric cancer: indications and impact of angiogenesis inhibitors
-
4:19
antiangiogenic treatments for metastatic colorectal cancer
-
2:34
dr. kunz on angiogenesis inhibitors for the treatment of metastatic gastric cancer
-
19:53
stage ii colon cancer: can we refine the selection for adjuvant treatment?
-
22:46
mutational testing and the treatment of colorectal cancer
-
7:54
anti-angiogenesis drugs, part iii
-
1:50
dr. eckhardt discusses angiogenesis inhibitors in mcrc
-
0:42
dr. fakih on anti-angiogenesis versus anti-egfr therapy in colon cancer
-
6:32
antiangiogenic therapy for metastatic colorectal cancer
-
51:20
itesm cancer lectures: angiogenesis
-
35:27
expert perspectives: optimizing late-line therapy for patients with metastatic colorectal cancer
-
5:04
a new hope
-
28:29
metastatic colorectal cancer: optimizing dosing strategy for late-line therapies